In conjunction with in vitro testing, the results demonstrated that the company's ARYMO ER tablets, in comparison to non-abuse-deterrent morphine sulfate extended-release
tablets, have increased resistance to cutting, crushing, grinding or breaking using a variety of tools.
Relative to morphine sulfate extended-release
tablets, these properties of MorphaBond increase resistance to cutting, crushing, or breaking using a variety of tools.
Zydus recently expanded its controlled substance portfolio with the launch of morphine sulfate extended-release
The drug's maker, Purdue Pharma, manufactures several other opioids, including transdermal buprenorphine, injectable and oral hydromorphone, morphine sulfate extended-release
tablets, and extended-release oxycodone without naloxone.
AVINZA (oral morphine sulfate extended-release
capsules) is the first true once-a-day treatment for chronic moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time.
Morphine sulfate extended-release
capsules, USP are an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, added the company.
US-based specialty pharmaceutical firm Upsher-Smith Laboratories will unveil the generic version of its Morphine Sulfate extended-release
(ER) capsules, CII on 4 September 2013.
Par purchased morphine sulfate extended-release
capsules (Kadian), fentanyl transdermal system CII, (Duragesic), nifedipine extended-release tablets (Adalat CC), diltiazem hydrochloride extended-release capsules, (Cardizem CD), and metoclopramide hydrochloride tablets (Reglan).
WASHINGTON -- Actavis has begun shipping morphine sulfate extended-release
capsules, USP C11, an authorized generic of Kadian.
The company added that the Morphine Sulfate Extended-release
(ER) Tablets are the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.
27 October 2011 - US Mylan Inc (NASDAQ:MYL) said today that its Mylan Pharmaceuticals subsidiary had obtained final US Food and Drug Administration (FDA) approval for its Morphine Sulfate Extended-release
(ER) Tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin.
has received approval of its ANDA for morphine sulfate extended-release
tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.